Raia Drogasil stock heads into an earnings test
Published on 11/03/2026 at 01:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRaia Drogasil faces earnings scrutiny
- MarketBeat expected Raia Drogasil to publish quarterly results after the November 3, 2026, market close.
- The previous quarter matched earnings expectations but missed the revenue forecast.
- RD Saúde operates pharmacy, digital commerce and healthcare services in Brazil.
Raia Drogasil is heading into a scheduled earnings release after MarketBeat reported on October 27, 2026, that the company was expected to publish quarterly results after the market close on Tuesday, November 3. Analysts cited by MarketBeat expected earnings of 0.05 US dollars per share and revenue of 2.41 billion US dollars for the quarter.
Estimates set the near-term test
The upcoming report will give investors a fresh view of sales momentum and profitability at RD Saúde, the company's current operating name. The focus is likely to remain on whether earnings can hold up while revenue growth catches up with expectations.
MarketBeat said Raia Drogasil matched the consensus earnings estimate in its previous quarterly release on August 4, but revenue of 2.17 billion US dollars was below the 2.32 billion US dollar estimate. The same report cited expected full-year earnings of 0.17 US dollars per share and next-year earnings of 0.24 US dollars per share.
The MarketBeat earnings preview also reported that Jefferies Financial Group raised its rating to Buy on October 18 and set a 5.20 US dollar price target. That view represents an analyst opinion rather than a company forecast.
RD Santé serves Brazil's health market
RD Saúde operates pharmacy stores under the Raia and Drogasil brands, selling prescription medicines, over-the-counter products, vitamins, personal-care items, beauty products and other health-related merchandise. The company also offers digital purchasing and delivery services and pharmacy-based healthcare initiatives in Brazil.
The company was created in 2011 through the merger of Drogasil and Droga Raia. Its combination of physical pharmacies, digital channels and healthcare services gives it a broad position in Brazil's pharmacy retail market, while the scheduled results will show how that model is translating into sales and earnings.
Raia Drogasil at a glance
- Company: Raia Drogasil S.A., operating as RD Saúde
- ISIN: BRRADLACNOR0
- B3 ticker: RADL3
- Business: Pharmacy retail, digital commerce and healthcare services
- Primary market: Brazil
- Next reported event: Quarterly results expected after the November 3, 2026, market close
